Omega-3 Oils (eBook)
312 Seiten
Elsevier Science (Verlag)
978-0-12-804347-9 (ISBN)
This book addresses new applications of omega-3 fatty acids from both plant and marine sources in food supplements and pharmaceuticals and covers three basic areas: structure and function, production and processing, and health effects. The authors review the latest clinical evidence on the impact of consumption of omega-3 polyunsaturated fatty acids on prevalent human diseases such as inflammation-related illnesses in general and cardiovascular illnesses in particular. They also examine technologies to purify marine oils and protect them against oxidation as well as novel techniques for their incorporation into foods. - Covers the role omega-3 plays in general health and disease and includes several reviews on the latest clinical evidence- Explains different methods to deliver omega-3 to the consumer, through various methods including food fortification, nutritional supplements, and more- Considerations for the processing of omega-3 oils to minimize conditions that could destroy the nutrtional properties.
Clinical Effects of n-3 PUFA Supplementation in Human Health and Inflammatory Diseases
Dr. Jennifer M. Monk14, David N. McMurray12 and Robert S. Chapkin13*, 1Program in Integrative Nutrition & Complex Diseases; 2Department of Microbial & Molecular Pathogenesis, Texas A&M University Health Science Center, College Station, TX; 3Vegetable Fruit Improvement Center, Texas A&M University, College Station, Texas; 4Postdoctoral Fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC, PDF-388466-2010)
Introduction
Long chain n-3 polyunsaturated fatty acids (PUFA) derived from marine sources, namely eicosapentaenoic acid (EPA; 20:5Δ5,8,11,14,17) and docosahexaenoic acid (DHA; 22:6Δ4,7,10,13,16,19), have been shown to exhibit beneficial anti-inflammatory effects in multiple inflammatory disease states (Chapkin et al., 2007; Sijben & Calder, 2007). Within the typical American diet, the daily consumption of n-3 PUFA is between 0.7 and 1.6 g, which is equivalent to approximately 0.2–0.7% of total calories (Conquer & Holub, 1998; Kris-Etherton et al., 2000). Of this, the amount of fish-derived long chain n-3 PUFA (i.e., EPA and DHA) is reported to be less than 0.1–0.2 g per day with the majority being comprised of alpha-linolenic acid (ALA), the plant based form of n-3 PUFA (Kim et al., 2010b). In human clinical trials, n-3 PUFA intake levels, mainly in the form of EPA and DHA, are consumed at 1–9 g/day, which corresponds to 0.45–4.0% of calories (Kelley et al., 1998, 1999; Rees et al., 2006; Thies et al., 2001). This physiological range is comparable to levels consumed in traditional Japanese diets (containing 1–2% of daily energy as long chain n-3 PUFA) or by the Greenland Inuit, consuming 2.7–6.3% of daily energy (6–14 g/day) (Damsgaard et al., 2008; Feskens & Kromhout, 1993; Nagata et al., 2002; Okuyama et al., 1996).
Research conducted to elucidate the beneficial effects of n-3 PUFA on both physiological and pathophysiological processes highlights the attempt to determine if this bioactive food component is beneficial with respect to both preventing disease onset and/or improving the clinical outcomes in already established pathologies. Our objective in this chapter is to highlight some of the recent findings pertaining to the impact of n-3 PUFA consumption on prevalent human diseases, which include an inflammatory dimension, and thus, are most likely to be impacted by an anti-inflammatory food component. Since this is an expansive topic that is both an active and prolific area of research, where appropriate, the reader is referred to more specific comprehensive review papers for further details. Additionally, in making comments on the outcomes from clinical trials, we preferentially selected meta-analyses, thereby systematically providing the findings from multiple studies to allow for the opportunity to make more conclusive comments on what is currently known.
Putative Mechanisms of n-3 PUFA Action
Following n-3 PUFA consumption, tissue enrichment readily occurs, and this is particularly apparent in diverse immunological cell populations wherein n-3 PUFA are incorporated into both plasma and intracellular membranes as summarized in detail elsewhere (Calder, 2007). Generally, increasing the dietary intake of n-3 PUFA from fish oil results in increased proportions of the respective n-3 PUFA (DHA and EPA) into cells and, typically, this occurs at the expense of n-6 PUFAs, especially linoleic and arachidonic acid, therefore the cellular level is readily influenced by diet (Calder, 2007; Chapkin et al., 2007;). Further, time-course studies indicate that the incorporation of EPA and DHA into human immune cells reaches its peak within 4 weeks post initiation of dietary intake in a dose-response manner, as reviewed elsewhere (Calder, 2007). The sub-cellular incorporation of n-3 PUFA is localized primarily within the membrane phospholipids at the sn-2 position (Anderson & Sperling, 1971; Stillwell & Wassall, 2003). In this connection, dietary n-3 PUFA have been shown to specifically alter plasma membrane micro-organization (lipid rafts) at the immunological synapse between T cells and antigen-presenting cells ultimately suppressing signal transduction and nuclear translocation/activation of transcription factors (Fan et al., 2004; Kim et al., 2008, 2010; Yog et al., 2010). Interestingly, DHA and EPA enrichment has been shown to occur in both membrane lipid raft and non-raft membrane fractions isolated from CD4+ T cells (Switzer et al., 2004). Therefore, the presence of long chain n-3 PUFA in the membrane imparts unique physiochemical properties to cellular membranes, and DHA-induced alterations in membrane structure and function have been proposed to underlie the beneficial effects of n-3 PUFA (Chapkin et al., 2007; Ma et al., 2004, 2004b; Seo et al., 2006; Stillwell & Wassall, 2003).
Generally, n-3 PUFA (DHA and EPA) exert anti-inflammatory and immune suppressive functions, which may explain the beneficial role of this bioactive food component in human clinical trials and supplementation studies. The mechanisms through which n-3 PUFA exert these effects are broadly based and represent an active and ongoing research front. Appropriately crafted studies in animal and cell culture models relevant to human disease states have provided insight into the multiple mechanisms through which n-3 PUFA appear to play a beneficial role in either preventing the onset or slowing the progression of many human pathologies. Interestingly, n-3 PUFA appear to mediate effects at multiple stages of cellular complexity and organization affecting signaling pathways generated at the level of tissue, the cell membrane, or the intracellular second messengers and transcription factors, thereby ultimately impacting gene expression (Fig. 2.1). Thus, the pleiotropic effects of n-3 PUFA on physiological processes demonstrate that this biologically relevant bioactive food component exerts a more diverse and potent effect compared to other nutraceuticals.
Fig. 2.1 n-3 PUFA mechanisms of action. The presence of n-3 PUFA in the membrane imparts unique physiochemical properties to cellular phospholipid domains (lipid rafts), ultimately affecting membrane structure and function, leading to alterations in signaling cascades. n-3 PUFA can modulate inflammation by suppressing nuclear receptor activation (e.g., NF-κB) and by opposing n-6 PUFA-derived eicosanoids. Solid arrows indicate direct effects, hammerhead arrows indicate inhibition, and dotted arrows indicate migration.
Putative mechanisms of action elicited by n-3 PUFA impact diverse physiological processes including cell membrane structure/function, eicosanoid signaling, nuclear receptor activation, and whole-body glucose and lipid metabolism, thereby providing significant protection against a variety of apparently unrelated human diseases (Chapkin et al., 2007; Hu et al., 2003; Jump et al., 2005; Lupton & Chapkin, 2003; Stulnig, 2003).
Immunmodulatory effects are elicited by n-3 PUFA through multiple mechanisms, including diminishing T-cell proliferative capacity in response to mitogenic and antigenic stimulation (Anderson & Fritsche, 2004; Arrington et al., 2001, 2001b; Zhang et al., 2005, 2006). These suppressive effects have also been observed in the dendritic cell, endothelial cell, macrophage, and neutrophil components of the inflammatory response (Bagga et al., 2003; Hughes & Pinder, 2000; Massaro et al., 2008; Novak et al., 2003; Prescott, 1984; Zeyda et al., 2005). Additionally, dietary n-3 PUFA modulate components of intracellular signaling pathways regulating T-cell activation are summarized in detail elsewhere (Chapkin et al., 2009). Alterations in T-cell function by n-3 PUFA could reflect direct effects on the ability of target T-cell populations to respond to activating stimuli and/or indirect effects on the activity of accessory cells (non-T-cell populations), which promote T-cell activation or a combination of these two distinct mechanisms (Chapkin et al., 2009).
It is well documented that EPA and DHA (n-3 PUFA) supplant n-6 PUFA, principally linoleic acid and arachidonic acid (the major eicosanoid precursor), and can therefore dramatically alter both the spectrum and biological properties impacted by cyclooxygenase (COX) and lipoxygenase (LOX) derived metabolites (Chapkin et al., 2007; Smith, 2005). Arachidonic acid (n-6 PUFA) derived metabolites such as COX-derived prostaglandin (PG)-E2 and LOX-derived leukotriene (LT)-B4 are largely pro-inflammatory...
Erscheint lt. Verlag | 19.8.2015 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete |
Studium ► 1. Studienabschnitt (Vorklinik) ► Histologie / Embryologie | |
Studium ► Querschnittsbereiche ► Infektiologie / Immunologie | |
Naturwissenschaften ► Chemie ► Technische Chemie | |
Technik ► Lebensmitteltechnologie | |
ISBN-10 | 0-12-804347-4 / 0128043474 |
ISBN-13 | 978-0-12-804347-9 / 9780128043479 |
Haben Sie eine Frage zum Produkt? |
Größe: 5,3 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich